This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Levitzki, A. Search for Related Content PubMed PubMed Citation Articles by Levitzki, A. Pubmed/NCBI databases Substance via MeSH

(Circulation Research. 2001;88:e77.)
© 2001 American Heart Association, Inc.

Letters to the Editor

Quinoxalines Versus Indolinones as Inhibitors of Restenosis

Alexander Levitzki¹

¹ Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, and, Institute for Advanced Studies, The Hebrew University of Jerusalem, Jerusalem, 91904, Israel, levitzki@vms.huji.ac.il

To the Editor:

We would like to point out several issues related to citations of the scientific literature in an article by Yamasaki et al.¹ We would like to emphasize that quinoxalines were the first compounds showing excellent efficacy in inhibiting balloon injury–induced stenosis in pigs and rats. Reference 20 in the article by Yamasaki et al, which describes this study, is not quoted correctly, as it omits most of the authors of this pioneering study. The accurate reference is the second citation in the reference section of this letter.² The efficacy of a quinoxaline in rats is described in the study by Fishbein et al.³

Reference 25, which cites quinoxalines as being synthesized by Muranaka et al,⁴ is actually wrong. This reference describes indolinones, the very compounds Yamasaki et al¹ describe in their own study. Quinoxalines were first described in the study by Kovalenko,⁵ which should have been quoted instead of Reference 25, crediting the quinoxalines as selective and potent platelet-derived growth factor receptor (PDGFR) kinase inhibitors.

References

1. Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G, Lipson KE. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res. 2001;88:630–636.

2. Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, Gertz SD. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 1998;97:1960–1969.

3. Fishbein I, Waltenberger J, Banai S, Rabinovich L, Chorny M, Levitzki A, Gazit A, Huber R, Mayr U, Gertz SD, Golomb G. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol. 2000;20:667–676.

4. Muranaka Y, Yamasaki Y, Nozawa Y, Terakawa H, Tanahashi Y, Oda N, Satoh A, Asao T, Miyake H, Matsuura N. TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries. J Pharmacol Exp Ther. 1998;285:1280–1286.

5. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106–6114.

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Levitzki, A. Search for Related Content PubMed PubMed Citation Articles by Levitzki, A. Pubmed/NCBI databases Substance via MeSH